Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Shares Outstanding (Weighted Average) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $24.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 117.11% to $24.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.4 million, a 117.11% increase, with the full-year FY2025 number at $24.4 million, up 117.11% from a year prior.
  • Shares Outstanding (Weighted Average) was $24.4 million for Q4 2025 at Artiva Biotherapeutics, roughly flat from $24.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $24.4 million in Q4 2025 to a low of $800541.0 in Q3 2023.
  • A 3-year average of $10.9 million and a median of $6.9 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 1.29% in 2024, then surged 2906.08% in 2025.
  • Artiva Biotherapeutics' Shares Outstanding (Weighted Average) stood at $802747.0 in 2023, then soared by 1302.54% to $11.3 million in 2024, then surged by 117.11% to $24.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Shares Outstanding (Weighted Average) are $24.4 million (Q4 2025), $24.4 million (Q3 2025), and $24.4 million (Q2 2025).